Fennec Pharmaceuticals Inc.

TSX:FRX.TO

Biotechnology

Healthcare
$19.17 -1.71%

-$0.22 today

Market cap
$676.80M
Beta
1.08
P/E (TTM)
-36.5
EPS (TTM)
-$0.24
52W Low $7.59High $14.24

Volume 0.00M

Average 0.00M

FRX.TO Research & Development

Spending on developing new products, technologies, and improvements to existing offerings.

Fennec Pharmaceuticals Inc.TSX: FRX.TO

Research & Development · Q1 FY2026 · quarter ended Mar 2026

Research & development declines year over year

Q1 FY2026 research & development of $48.87K fell 48.0% year over year, in line with the -48.4% change in trailing-twelve-month research & development. Sequentially, it rose 140.7% from the prior quarter. Over 3 fiscal years it compounded at -58.4% a year.

Context

  • Research & development amounted to 0.6% of revenue in FY2025, unchanged from a year earlier.
  • Research & development increased in 1 of the last 3 fiscal years.

What to watch

Whether quarterly growth of -48.0% holds above the trailing-twelve-month pace of -48.4%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$48.87K+140.7% QoQ
Last fiscal yearDec 2025
$254.38K-17.1% YoY
LTMMar 2026
$205.18K-48.4% YoY
Research & Development past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-48.0%——
1 year-17.1%——
3-year CAGR-58.4%——
5-year CAGR——
10-year CAGR——

Research & Development history

USD · from the income statement

Latest · FY2025
254.38K USD
Year-over-year change
-17.1%
4-year CAGR
-52.5%

Research & Development vs competitors

How FRX.TO compares with its peers on the latest reported figures

  • Peers report in different currencies, so research & development is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -48.4% is the 4th highest of 5, against a peer median of +13.5%.
  • Research & development amounts to 0.4% of revenue for FRX.TO, versus a peer median of 0.0%.
FRX.TO Competitors
Research & Development for FRX.TO and competitors
Company Period LTM YoY 3-year CAGR% of revenue
EPRX.TOEupraxia Pharmaceuticals Inc.LTM Mar 2026$27.07M USD+139.8%+7.0%—
PRN.TOProfound Medical Corp.LTM Mar 2026$20.97M USD+17.5%+12.6%111.8%
OGI.TOOrganiGram Holdings Inc.LTM Mar 2026CA$10.02M CAD+9.4%—3.7%
HBP.TOHelix BioPharma Corp.LTM Apr 2026CA$1.62M CAD-72.8%-7.7%—
FRX.TOFennec Pharmaceuticals Inc.LTM Mar 2026$205.18K USD-48.4%-58.4%0.4%
WEED.TOCanopy Growth CorporationLTM Mar 2026CA$0 CAD——0.0%
DR.TOMedical Facilities CorporationLTM Mar 2026$0 USD——0.0%
TSND.TOTerrAscend Corp.LTM Mar 2026$0 USD——0.0%
Peer median (excluding FRX.TO) —+13.5%+7.0%0.0%

Competitors are the stored peer set for FRX.TO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue01.54M21.25M47.54M44.64M
Cost of Revenue086K1.26M3.18M3.76M
Gross Profit01.45M19.99M44.35M40.88M
Gross Margin—94.4%94.1%93.3%91.6%
Research & Development4.98M3.53M56K307K254.38K
Selling, General & Admin12.24M20.51M32.71M41.48M46.91M
Operating Expenses17.22M24.04M32.76M41.79M47.22M
Depreciation & Amortization17.22M149K287K800K103K
EBITDA(17.19M)(22.74M)(12.65M)4.8M(7.45M)
EBITDA Margin—-1481.2%-59.5%10.1%-16.7%
Operating Income(17.22M)(22.59M)(12.77M)2.57M(6.35M)
Operating Margin—-1471.6%-60.1%5.4%-14.2%
Interest Income54K195K441K1.68M800.78K
Interest Expense126K978K3.39M4.07M2.18M
Other Income / Expenses(123K)(1.13M)(3.27M)(2.64M)(3.29M)
Income Before Tax(17.35M)(23.71M)(16.05M)(71K)(9.64M)
Pre-Tax Margin—-1544.9%-75.5%-0.1%-21.6%
Income Tax Expense110K147K0365K106K
Net Income(17.46M)(23.86M)(16.05M)(436K)(9.74M)
Net Margin—-1554.5%-75.5%-0.9%-21.8%
EPS (Basic)(0.67)(0.91)(0.60)(0.02)(0.34)
EPS (Diluted)(0.67)(0.91)(0.60)(0.02)(0.34)
Weighted Avg Shares25.89M26.28M26.57M21.8M28.58M
Weighted Avg Shares (Diluted)26.01M26.28M26.57M27.3M28.58M

Fennec Pharmaceuticals Inc.

TSX:FRX.TO

Intrinsic Alpha fair value

Locked

Current Price

$19.17

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.